- 32
- 61 277
Lantern Pharma (NASDAQ: LTRN)
United States
เข้าร่วมเมื่อ 30 ก.ค. 2019
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. Lantern’s lead development programs include two Phase 2 clinical programs and multiple upcoming Phase 1 clinical trials anticipated for 2023.
[LTRN Webinar] Power of AI in Drug Development-Predicting Blood Brain Barrier Permeability with RADR
Lantern Pharma Webinar Wednesday - Power of AI in Drug Development-Predicting Blood Brain Barrier Permeability with RADR - featuring Rick Fontenot, M.S., Data Scientist of Lantern Pharma
0:00 introduction
1:42 What is blood brain barrier(BBB)?
3:04 Significance of BBB in cancer drug development
4:20 How do drugs cross BBB?
7:05 RADR AI insights on BBB - using machine learning
15:40 How did RADR gather data to build the BBB model?
18:58 Power of predicting BBB permeability with RADR
0:00 introduction
1:42 What is blood brain barrier(BBB)?
3:04 Significance of BBB in cancer drug development
4:20 How do drugs cross BBB?
7:05 RADR AI insights on BBB - using machine learning
15:40 How did RADR gather data to build the BBB model?
18:58 Power of predicting BBB permeability with RADR
มุมมอง: 2 420
วีดีโอ
Lantern Pharma | Third Quarter 2024 Operating & Financial Results
มุมมอง 3.4Kหลายเดือนก่อน
0:00 Intro 4:42 2024 3rd Quarter Highlights 12:58 Financial Highlights 16:25 Lantern's pipeline 18:10 Starlight Therapeutics 22:20 Progress with LP-184 & LP-284 26:05 Harmonic™ Phase 2 Clinical Trial 28:13 R&D Updates 42:08 2024-25 Objectives 44:12 Q&A
![[LTRN Webinar] Actuate Therapeutics x Lantern Pharma AI Collaboration](http://i.ytimg.com/vi/HwaxjU_PRzQ/mqdefault.jpg)
[LTRN Webinar] Actuate Therapeutics x Lantern Pharma AI Collaboration
มุมมอง 11Kหลายเดือนก่อน
Actuate Therapeutics, Inc. & Lantern Pharma Inc. (Nasdaq: LTRN)'s AI Collaboration - Using Lantern’s AI Platform to Accelerate & Advance The Development of a Novel Cancer Drug - The Elraglusib Story, Featuring Andrew Mazar, COO of Actuate therapeutics and Joseph McDermott, computational biologist of Lantern Pharma. Timestamps 0:00 Introducing the speakers 1:15 Introducing Actuate Therapeutics 2...
![[LTRN Webinar] Lantern Pharma Webinar Wednesdays - Childhood Cancer Awareness Month](http://i.ytimg.com/vi/sLJjhFuR-KU/mqdefault.jpg)
[LTRN Webinar] Lantern Pharma Webinar Wednesdays - Childhood Cancer Awareness Month
มุมมอง 3.8K3 หลายเดือนก่อน
Panna Sharma, CEO and President of Lantern Pharma and Dr. Reggie Ewesuedo, Vice president of Clinical Development of Lantern Pharma talks about the recent announcement of our drug candidate, LP-184, receiving three additional rare pediatric disease designation in ultra-rare children’s cancers and Lantern Pharma’s continuous effort to develop a new treatment options for childhood cancers. 0:00 I...
![[LTRN Webinar]Harmonic Clinical Trial for Never Smokers with NSCLC-Preliminary patient data readout](http://i.ytimg.com/vi/Iv8fzWtpX2E/mqdefault.jpg)
[LTRN Webinar]Harmonic Clinical Trial for Never Smokers with NSCLC-Preliminary patient data readout
มุมมอง 474 หลายเดือนก่อน
0:00 Introduction of Dr. Reggie Ewesuedo 1:14 Overview of the Harmonic Trial 3:13 Preliminary clinical data pf 7 initial patients 6:23 The significance of the preliminary data 8:55 What to expect - expansion phase of the trial
Lantern Pharma | Second Quarter 2024 Operating & Financial Results Conference Call
มุมมอง 1.2K4 หลายเดือนก่อน
0:00 Intro 3:40 2024 Q2 Highlights 15:10 Financial Highlights 18:55 Harmonic Highlights 36:10 Starlight Therapeutics 37:10 Lantern Pharma Webinar Wednesday 38:00 Recent publications 42:00 Q&A 56:17 Ending Remarks
![[LTRN Webinar] Starlight Therapeutics - Born from AI, Lighting the Way in CNS Cancer Treatment](http://i.ytimg.com/vi/ueCOFRKDwDo/mqdefault.jpg)
[LTRN Webinar] Starlight Therapeutics - Born from AI, Lighting the Way in CNS Cancer Treatment
มุมมอง 1064 หลายเดือนก่อน
0:00 Intro & How starlight is born 7:43 Why is Starlight Therapeutics so unique? 9:50 Starlight Therapeutic's now and the future 12:00 Q&A
![[LTRN Webinar] STAR-001 in Multiple Brain and CNS Cancers | Dr. Marc Chamberlain](http://i.ytimg.com/vi/aK8A6NkJI-8/mqdefault.jpg)
[LTRN Webinar] STAR-001 in Multiple Brain and CNS Cancers | Dr. Marc Chamberlain
มุมมอง 1046 หลายเดือนก่อน
0:00 Intro 1:25 Dr. Marc Chamberlain's background 1:39 Starlight's Focus 1. Glioblastoma 3:18 Starlight's Focus 2. Brain Metastases 4:53 Starlight's Focus 3. Pediatric Cancers 5:43 Unique Features of STAR-001 9:45 Current & Future Clinical Trials for STAR-001 14:12 Learn more
![[LTRN Webinar] - LP-184 in pancreatic cancer and other solid tumors with Dr. Igor from FCCC](/img/n.gif)
[LTRN Webinar] - LP-184 in pancreatic cancer and other solid tumors with Dr. Igor from FCCC
มุมมอง 2.7K6 หลายเดือนก่อน
#PancreaticCancer #CancerAwareness #webinar 0:00 Intro 0:30 Current challenges for pancreatic cancer 1:09 Developing new therapeutic options with LP-184 3:54 LP-184's mechanism of action 6:05 Phase 1A trial for LP-184 in solid tumors and GBM
[LTRN Webinar] Precision Medicine for Bladder Cancer: Now is the Time with Dr. Pappot of UCPH
มุมมอง 246 หลายเดือนก่อน
#BladderCancer #Cancerawareness #webinar 0:00 Introduction : Dr. Pappot's background and research interest 2:32 Current treatment options for bladder cancer patients 6:32 Current challenges for bladder cancer 10:38 Precision medicine for bladder cancer 16:13 Collaboration with Lantern Pharma
Lantern Pharma | First Quarter 2024 Operating & Financial Results Conference Call
มุมมอง 4.6K7 หลายเดือนก่อน
Lantern Pharma’s First Quarter Earnings Call 0:00 Introduction 4:57 Highlights 7:19 LTRN Pipeline 12:56 Starlight Pipeline 17:07 Financials 21:44 Starlight 29:04 ADC 33:00 Webinar Wednesdays 35:05 Publications / Posters 38:06 2024 Objectives $LTRN #Earningscall
[LTRN Webinar] LP-300 in never smokers with non-Small Cell Lung cancer with Dr. Treat from FCCC
มุมมอง 4.7K8 หลายเดือนก่อน
[LTRN Webinar] LP-300 in never smokers with non-Small Cell Lung cancer with Dr. Treat from FCCC
Creating an AI-Driven Biotech for Cancer Drug Development | Panna Sharma | Nasdaq: LTRN
มุมมอง 20311 หลายเดือนก่อน
Join our CEO and President, Panna Sharma, in this interview by Andrii Buvailo. Lantern Pharma is a Nasdaq-traded clinical-stage AI-led drug discovery company with an impressive portfolio of cancer drug candidates in clinical and preclinical programs. In this interview, Panna details the journey of building a biotech company at the forefront of AI-driven cancer drug development. 0:00 Introductio...
Lantern Pharma | Third Quarter 2023 Operating & Financial Results Conference Call
มุมมอง 12Kปีที่แล้ว
Lantern Pharma's 2023 3rd quarter Earnings call. 0:00 Introduction 2:40 Lantern Pharma 3rd quarter overview 8:18 3rd Quarter Highlights 10:08 Financial Highlights 14:30 Detailed quarterly highlights 28:05 Question 1 - plans for refining the indications (LP-184 / LP-284) 29:17 Question 2 - plans for sharing initial data for trials 31:45 Question 3 - Timing for potential readouts 33:45 Question 4...
Think Equity Conference 2023 | Overview of Lantern Pharma Inc. (Nasdaq: LTRN) by Panna Sharma
มุมมอง 716ปีที่แล้ว
Panna Sharma, CEO and president of Lantern Pharma Inc. (Nasdaq: LTRN), presented an overview of the company at the Think Equity Conference 2023.
Fireside with CEO Panna Sharma | Lytham Partners Investor Conference| Lantern Pharma
มุมมอง 954ปีที่แล้ว
Fireside with CEO Panna Sharma | Lytham Partners Investor Conference| Lantern Pharma
How AI is Accelerating Advancements in Oncology | NASDAQ Breakthrough Economy | Lantern Pharma
มุมมอง 5Kปีที่แล้ว
How AI is Accelerating Advancements in Oncology | NASDAQ Breakthrough Economy | Lantern Pharma
Lantern Pharma | First Quarter 2023 Operating & Financial Results Conference Call
มุมมอง 128ปีที่แล้ว
Lantern Pharma | First Quarter 2023 Operating & Financial Results Conference Call
Synthetic Lethality Key Opinion Leader(KOL) Webinar
มุมมอง 5Kปีที่แล้ว
Synthetic Lethality Key Opinion Leader(KOL) Webinar
Lantern Pharma | Fourth Quarter 2022 Operating & Financial Results Conference Call
มุมมอง 41ปีที่แล้ว
Lantern Pharma | Fourth Quarter 2022 Operating & Financial Results Conference Call
Lantern Pharma | Third Quarter 2022 Operating & Financial Results Conference Call
มุมมอง 29ปีที่แล้ว
Lantern Pharma | Third Quarter 2022 Operating & Financial Results Conference Call
Childhood Cancer Awareness Month Key Opinion Leader(KOL) Webinar
มุมมอง 44ปีที่แล้ว
Childhood Cancer Awareness Month Key Opinion Leader(KOL) Webinar
Lantern Pharma | Second Quarter 2022 Operating & Financial Results Conference Call
มุมมอง 29ปีที่แล้ว
Lantern Pharma | Second Quarter 2022 Operating & Financial Results Conference Call
Brain Tumor Awareness Month Glioblastoma(GBM) Key Opinion Leader(KOL) Webinar
มุมมอง 69ปีที่แล้ว
Brain Tumor Awareness Month Glioblastoma(GBM) Key Opinion Leader(KOL) Webinar
World Pancreatic Cancer Day Key Opinion Leader(KOL) Webinar
มุมมอง 144ปีที่แล้ว
World Pancreatic Cancer Day Key Opinion Leader(KOL) Webinar
Lantern Pharma | First Quarter 2022 Operating & Financial Results Conference Call
มุมมอง 28ปีที่แล้ว
Lantern Pharma | First Quarter 2022 Operating & Financial Results Conference Call
Harmonic Clinical Trial For Patients with NSCLC - Non-Small Cell Lung Cancer is enrolling patients
มุมมอง 1052 ปีที่แล้ว
Harmonic Clinical Trial For Patients with NSCLC - Non-Small Cell Lung Cancer is enrolling patients
Lantern Pharma's AI-Based Drug Discovery and Development Targeting Cancer
มุมมอง 2354 ปีที่แล้ว
Lantern Pharma's AI-Based Drug Discovery and Development Targeting Cancer
The Science Behind Lantern Pharma's Cancer Drug Development
มุมมอง 2084 ปีที่แล้ว
The Science Behind Lantern Pharma's Cancer Drug Development
Working at Lantern Pharma - Cultivating Passion and Progress
มุมมอง 2755 ปีที่แล้ว
Working at Lantern Pharma - Cultivating Passion and Progress